Technology Appraisal Committee Meeting (Committee A)

**Meeting held via Zoom Video Conferencing**

## Minutes: Confirmed

## Date and Time: Tuesday 24 March 2020 (10am – 4.40pm)

### Present:

1. Dr Jane Adam (Chair) Present for all notes
2. Dr Brain Shine (Vice Chair) Present for all notes
3. Dr Alice Turner Present for all notes
4. John Cairns Present for notes 1 to 7
5. G.J. Melendez-Torres Present for all notes
6. Dr Mark Upton Present for all notes
7. Mr Min Ven Teo Present for notes 1 to 7
8. Dr Mohit Sharma Present for all notes
9. Ms Pamela Rees Present for all notes
10. Peter Baker Present for all notes
11. Mr Richard Ballerand Present for all notes
12. Dr Rita Faria Present for all notes
13. Mr Stephen Sharp Present for all notes
14. Dr Steve Edwards Present for notes 8 to 13
15. Steve O’Brien Present for notes 8 to 13

### In attendance:

* Helen Knight, Programme Director, NICE, Present for all notes
* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Marcia Miller, Administrator, NICE, Present for all notes
* Caroline Bregman, Technical Analyst, NICE, Present for notes 1 to 7
* Rufaro Kausi, Technical Adviser, NICE, Present for notes 1 to 7
* Marcela Haasova, Technical Analyst, NICE, Present for notes 8 to 13
* Joanna Richardson, Technical Adviser, NICE, Present for notes 8 to 13
* Steve Edwards, BMJ-TAG, Evidence Review Group, Present for notes 1 to 5
* Victoria Wakefield, BMJ-TAG, Evidence Review Group, Present for notes 1 to 5
* Gemma Marceniuk, BMJ-TAG, Evidence Review Group, Present for notes 1 to 5
* Nigel Armstrong, KSR, Evidence Review Group, Present for notes 8 to 11
* Isaac Corro Ramos, KSR, Evidence Review Group, Present for notes 8 to 11
* Hannah Penton, KSR, Evidence Review Group, Present for notes 8 to 11
* Rob Riemsma, KSR, Evidence Review Group, Present for notes 8 to 11
* Dr Deepa Arachchillage, Clinical Expert, Consultant Haematologist & Honorary Senior Lecturer, Present for notes 1 to 5
* Dr Andrew Veitch, Clinical Expert, Consultant Gastroenterologist, Present for notes 1 to 5
* Diane Eaton, Patient Expert, Present for notes 1 to 5
* Jo Jerrome, Patient Expert, Present for notes 1 to 5
* Professor Andrew Wardley, Clinical Expert, Consultant & MAHSC Professor in Breast Medical Oncology, Present for notes to 8 to 11
* Dr Mark Verrill, Clinical Expert, Consultant Medical Oncologist, Present for notes 8 to 11
* Tom Beattie, Patient Expert, Present for notes 8 to 11

### Non-public attendees:

* Rosalee Mason, Corporate Office Coordinator, NICE, Present for all notes
* Adam Storrow, Business Analyst, NICE, Present for all notes
* Ria Skelton, Editor, NICE, Present for all notes
* Laura Marsden, NICE, Present for all notes
* Jenna Dilkes, NICE, Present for all notes
* Gemma Barnacle, NICE, Present for all notes
* Maria Pitan, NICE, Present for all notes

## Notes

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on 25 February 2020.

## Appraisal of andexanet alfa for reversing anticoagulation [ID1101]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Portola Pharmaceuticals.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.

	1. Dr Deepa Arachchillage declared an indirect interest as she has given expert lectures in a meeting supported by Portola Pharmaceuticals, but had no direct contact with Portola Pharmaceuticals.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	2. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team, Dr Alice Turner, Ms Pamela Rees, Dr Rita Faria, who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
4. Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Roche.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.

	1. Professor Andrew Wardley declared a direct financial interest. He has received honoraria and travel bursaries from Roche and has worked on several Roche trials including the Catherine trial and other HER2 trials. He has received honoraria from numerous other companies, some of which are involved with treatments for HER2-positive breast cancer.
		1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
	2. Professor Mark Verrill declared a financial interest as he has received honoraria from Roche for speaking and advisory boards, consultancy and lecturing, and travel. He is principal investigator in several Roche-sponsored trials.
		1. It was agreed that this declaration would prevent them from participating in this section of the meeting.
	3. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the lead team, Dr Mohit Sharma, Mr Richard Ballerand and Dr Steve Edwards, who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Next Technology Appraisal (Committee A) Meeting: Tuesday 12 May 2020